Genentech (DNA) announced that the FDA approved its Herceptin cancer treatment for an expanded use for adjuvant treatment of HER2-positive node-positive breast cancer. The studies showed a 52% reduction in the recurrence of breast cancer of some 3,500 patients in two Phase III studies and is the only targeted biologic therapy approved for use in adjuvant and metastatic HER2-positive breast cancer.
Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment - surgery with or without radiation therapy - with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease. After three-and-a-half years in the study, 87 percent of women treated with Herceptin plus chemotherapy were disease free, compared to 71 percent of women treated with chemotherapy alone. A survival analysis conducted after patients had been followed for a median of 24 months showed a 33 percent reduction in the risk of death (based on a hazard ratio of 0.67), which is equivalent to a 49 percent improvement in overall survival.
DNA shares closed up 0.35% at $80.72 in regulartrading, but shares are up 0.9% at $81.45 in after-hours trading. DNA has a 52-week trading range of $75.58 to $100.20.
Jon C. Ogg
Jumat, 17 November 2006
Autodesk Up and On Auto Pilot
Autodesk (ADSK) just reported record quarter revenues of $457 million, just under the $457.25 million consensus estimate. It is not providing EPS because of the ongoing options review. ADSK closed up 1% at $27.00 in normal trading, but shares are up 6.4% to $39.35 in after-hours trading. The subscription revenues seem to be the game winner as the guidance seems in-line (although guidance may be conservative because of legal ramifications). ADSK 52-week trading range is $29.56 to $47.25.
There was a huge bright spot in what may be considered a slight beat with in-line guidance. Its subscription (recurring) revenues have now grown to $111 million, about 24% of revenues, and up 50% from last year. That is an impressive feat and has been one of the growth drivers to the company.
Total backlog was $352 million as of October 31, 2006, including $333 million of deferred revenues. Deferred subscription revenues increased $12 million sequentially to $275 million and there was $19 million of unshipped product orders at quarter end. Its DSO (days sales outstanding, or days to get paid!) also fell 1 day to 51 days.
There is also guidance (compared to street estimates) where available. Next quarter guidance: Net revenues for the fourth quarter of fiscal 2007 are expected to be between $490 million and $500 million ($495M estimate); following quarter guidance: Net revenues for the first quarter of fiscal 2008 are expected to be approximately flat with the fourth quarter of fiscal 2007. Fiscal 2007 guidance: For fiscal year 2007, net revenues are expected to be between $1.832 billion and $1.842 billion ($1.84B estimate). Fiscal 2008 guidance: For fiscal year 2008, net revenues are expected to be between $2.075 billion and $2.125 billion ($2.10 Billion estimates).
Jon C. Ogg
November 16, 2006
There was a huge bright spot in what may be considered a slight beat with in-line guidance. Its subscription (recurring) revenues have now grown to $111 million, about 24% of revenues, and up 50% from last year. That is an impressive feat and has been one of the growth drivers to the company.
Total backlog was $352 million as of October 31, 2006, including $333 million of deferred revenues. Deferred subscription revenues increased $12 million sequentially to $275 million and there was $19 million of unshipped product orders at quarter end. Its DSO (days sales outstanding, or days to get paid!) also fell 1 day to 51 days.
There is also guidance (compared to street estimates) where available. Next quarter guidance: Net revenues for the fourth quarter of fiscal 2007 are expected to be between $490 million and $500 million ($495M estimate); following quarter guidance: Net revenues for the first quarter of fiscal 2008 are expected to be approximately flat with the fourth quarter of fiscal 2007. Fiscal 2007 guidance: For fiscal year 2007, net revenues are expected to be between $1.832 billion and $1.842 billion ($1.84B estimate). Fiscal 2008 guidance: For fiscal year 2008, net revenues are expected to be between $2.075 billion and $2.125 billion ($2.10 Billion estimates).
Jon C. Ogg
November 16, 2006
Starbuck's Decaf (SBUX)
Starbuck's missed Wall St.'s revenue target and had poor earnings to boot. Some was due to changes in the company's accounting practices. Investors wanted revenue of $2.02 billion and the coffee retailer did $2 billion.
While the company's long range goal of hitting a total of 30,000 stores worldwide may not be in jeapordy, it may be set back a few days.
Starbuck's shares are off about 6% after hours to just above $37..
Douglas A. McIntyre can be reached at douglasamcintrye@247wallst.com. He does not own securities in companies that he writes about.
While the company's long range goal of hitting a total of 30,000 stores worldwide may not be in jeapordy, it may be set back a few days.
Starbuck's shares are off about 6% after hours to just above $37..
Douglas A. McIntyre can be reached at douglasamcintrye@247wallst.com. He does not own securities in companies that he writes about.
HP Earnings: Revenue Growth Light (HPQ)
HP announced earnings after the close. Revenue rose only 7% to $24.6 billion. Non-GAAP operating income rose from $1.5 billion in the quater a year ago to $1.9 billion. Desktop sales were flat while notebook unit sales rose 24%. Revenue at the imaging and printing unit rose 7%.
Enterprise storage and server revenue rose 4% to $4.7 billion. And, services revenue rose 5%.
Looking at the results, Paul Meeks, a hardware analyst interviews on CNBC, believes that the results only merit a share price of $40 to $41, which is where the stock trades now.
The forecast for the next quarter is for revenue to be in the $24.1 to $24.3 billion range and for the next fiscal $97 billion.
While revenue and EPS were slightly ahead of Wall St. estimates, the figures hardly constitute a blow out quarter. After rising 40% this year, the shares may be taking a pause.
Douglas A. McIntyre can be reached at douglasamcintyre@247wallst.com. He does not own securities in companies that he writes about.
Enterprise storage and server revenue rose 4% to $4.7 billion. And, services revenue rose 5%.
Looking at the results, Paul Meeks, a hardware analyst interviews on CNBC, believes that the results only merit a share price of $40 to $41, which is where the stock trades now.
The forecast for the next quarter is for revenue to be in the $24.1 to $24.3 billion range and for the next fiscal $97 billion.
While revenue and EPS were slightly ahead of Wall St. estimates, the figures hardly constitute a blow out quarter. After rising 40% this year, the shares may be taking a pause.
Douglas A. McIntyre can be reached at douglasamcintyre@247wallst.com. He does not own securities in companies that he writes about.
Kamis, 16 November 2006
Cramer Goes Back for Sears Holdings Again
Stock Tickers: SHLD
Tonight on CNBC's MAD MONEY Cramer also went over one of his long-standing favorite retail plays: Sears Holdings (SHLD).
He implied that SHLD stock is no different than investing in a company with a hedge fund manager trying to make his stocks go up. After today's drop of almost $10.00 after earnings, Cramer said the stock is going back up. He says this is a gift. He did tell on himself that you have heard him back this stock again and again. He said the bears are harping on same store sales and on inventory build-ups. He said it isn't a screaming buy because of it being a great retail play and not because it is a turnaround story. He says this is an investment ultimately in Eddie Lampert.
He has been there for the last $140 of upside, but he thinks it is going much higher and it may be a baby Berkshire Hathaway. Even though it is expensive on multiples, it will get more expensive and Eddie Lampert is a winner. The company allows Eddie Lampert to invest the profits from Sears and K-Mart elsewhere where he sees fit. The company made $101 million off of outside investments. The street doesn't like that they can't evaluate Sears as a retailer, but Cramer does.
Jon C. Ogg
November 16, 2006
Tonight on CNBC's MAD MONEY Cramer also went over one of his long-standing favorite retail plays: Sears Holdings (SHLD).
He implied that SHLD stock is no different than investing in a company with a hedge fund manager trying to make his stocks go up. After today's drop of almost $10.00 after earnings, Cramer said the stock is going back up. He says this is a gift. He did tell on himself that you have heard him back this stock again and again. He said the bears are harping on same store sales and on inventory build-ups. He said it isn't a screaming buy because of it being a great retail play and not because it is a turnaround story. He says this is an investment ultimately in Eddie Lampert.
He has been there for the last $140 of upside, but he thinks it is going much higher and it may be a baby Berkshire Hathaway. Even though it is expensive on multiples, it will get more expensive and Eddie Lampert is a winner. The company allows Eddie Lampert to invest the profits from Sears and K-Mart elsewhere where he sees fit. The company made $101 million off of outside investments. The street doesn't like that they can't evaluate Sears as a retailer, but Cramer does.
Jon C. Ogg
November 16, 2006
Cramer Backs Nike and Under Armour
Stock Tickers: NKE, UARM
Tonight on CNBC's MAD MONEY, Jim Cramer reviewed two stocks in the same sector that are both buys. He said which one you should own depends on your preference.
He said if a company has good management, that means they just aren't screwing up. Nike (NKE) and Under Armour (UARM) got lucky because Reebok screwed up by cutting marketing. Reebok's ad budget was only $7 million after Adidas bought them, and these two won as a result.
Cramer says that even though NKE and UARM are competing, they are different stocks for different investors. He says both are buys.
He says Nike (NKE) is the best for longer-lived investors that look for more stability and more predictability. He noted Under Armour (UARM) is the younger investor's stock that has a lot of room for growth down the road.
NKE trades cheaper, and is more defensive in nature trying toi preserve market share it has. UARM is a high-multiple stock that would crumble if the company messes up. Cramer said UARM's 31% market share could pass NKE's 36%, but UARM could take market share and NKE stock could still keep rising because they are different stories. He thinks UARM will take market share from Reebok since they aren't defending the brand. UARM is one that will get hurt bad if they ever miss an estimate by a penny, and NKE is the stable lion in the group.
UARM closed down 1.28% at $46.25 in regular trading, but shares are up almost 3% from teh close at $47.50 in after-hours trading. NKE closed down 0.25% at $95.23 in regular trading, but shares are up 0.9% at $95.92 in after-hours trading.
Jon C. Ogg
November 16, 2006
Tonight on CNBC's MAD MONEY, Jim Cramer reviewed two stocks in the same sector that are both buys. He said which one you should own depends on your preference.
He said if a company has good management, that means they just aren't screwing up. Nike (NKE) and Under Armour (UARM) got lucky because Reebok screwed up by cutting marketing. Reebok's ad budget was only $7 million after Adidas bought them, and these two won as a result.
Cramer says that even though NKE and UARM are competing, they are different stocks for different investors. He says both are buys.
He says Nike (NKE) is the best for longer-lived investors that look for more stability and more predictability. He noted Under Armour (UARM) is the younger investor's stock that has a lot of room for growth down the road.
NKE trades cheaper, and is more defensive in nature trying toi preserve market share it has. UARM is a high-multiple stock that would crumble if the company messes up. Cramer said UARM's 31% market share could pass NKE's 36%, but UARM could take market share and NKE stock could still keep rising because they are different stories. He thinks UARM will take market share from Reebok since they aren't defending the brand. UARM is one that will get hurt bad if they ever miss an estimate by a penny, and NKE is the stable lion in the group.
UARM closed down 1.28% at $46.25 in regular trading, but shares are up almost 3% from teh close at $47.50 in after-hours trading. NKE closed down 0.25% at $95.23 in regular trading, but shares are up 0.9% at $95.92 in after-hours trading.
Jon C. Ogg
November 16, 2006
Genetech Wins FDA Approval For Herceptin For Breast Cancer
Genentech (DNA) announced that the FDA approved its Herceptin cancer treatment for an expanded use for adjuvant treatment of HER2-positive node-positive breast cancer. The studies showed a 52% reduction in the recurrence of breast cancer of some 3,500 patients in two Phase III studies and is the only targeted biologic therapy approved for use in adjuvant and metastatic HER2-positive breast cancer.
Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment - surgery with or without radiation therapy - with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease. After three-and-a-half years in the study, 87 percent of women treated with Herceptin plus chemotherapy were disease free, compared to 71 percent of women treated with chemotherapy alone. A survival analysis conducted after patients had been followed for a median of 24 months showed a 33 percent reduction in the risk of death (based on a hazard ratio of 0.67), which is equivalent to a 49 percent improvement in overall survival.
DNA shares closed up 0.35% at $80.72 in regulartrading, but shares are up 0.9% at $81.45 in after-hours trading. DNA has a 52-week trading range of $75.58 to $100.20.
Jon C. Ogg
November 16, 2006
Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment - surgery with or without radiation therapy - with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease. After three-and-a-half years in the study, 87 percent of women treated with Herceptin plus chemotherapy were disease free, compared to 71 percent of women treated with chemotherapy alone. A survival analysis conducted after patients had been followed for a median of 24 months showed a 33 percent reduction in the risk of death (based on a hazard ratio of 0.67), which is equivalent to a 49 percent improvement in overall survival.
DNA shares closed up 0.35% at $80.72 in regulartrading, but shares are up 0.9% at $81.45 in after-hours trading. DNA has a 52-week trading range of $75.58 to $100.20.
Jon C. Ogg
November 16, 2006
Langganan:
Postingan (Atom)